(Q34383213)

English

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

0 references

Stephen T. Holgate

2

object named as

Stephen Holgate

1 reference

Europe PubMed Central

1 August 2017

William W Busse

1

object named as

William W Busse

1 reference

Europe PubMed Central

1 August 2017

author name string

Edward Kerwin

3

1 reference

Europe PubMed Central

1 August 2017

Yun Chon

4

1 reference

Europe PubMed Central

1 August 2017

Jingyuan Feng

5

1 reference

Europe PubMed Central

1 August 2017

Joseph Lin

6

1 reference

Europe PubMed Central

1 August 2017

Shao-Lee Lin

7

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

1 December 2013

1 reference

Europe PubMed Central

1 August 2017

American Journal of Respiratory and Critical Care Medicine

1 reference

Europe PubMed Central

1 August 2017

188

1 reference

Europe PubMed Central

1 August 2017

1294-1302

1 reference

Europe PubMed Central

1 August 2017

11

1 reference

Europe PubMed Central

1 August 2017

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Structure and signalling in the IL-17 receptor family

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Neutrophil Recruitment by Interleukin-17 into Rat AirwaysIn Vivo

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Interleukin-17 is a negative regulator of established allergic asthma

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Validation of the Cork-Southampton Food Challenge Outcome Calculator in a Canadian sample

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Trials and tribulations in identifying new biologic treatments for asthma

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201212-2318OC

21 January 2018

Identifiers

10.1164/RCCM.201212-2318OC

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34383213&oldid=1966662087"